Posted: August 14, 2022 at 2:33 am
CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.
Original post:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering
Posted: August 14, 2022 at 2:33 am
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release
View post:
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
Posted: August 14, 2022 at 2:33 am
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval
Posted: August 14, 2022 at 2:33 am
Conference call begins at 11:00 a.m. Eastern time today
Read the original:
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Posted: August 14, 2022 at 2:33 am
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.
View original post here:
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Posted: August 14, 2022 at 2:33 am
REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update.
Originally posted here:
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Posted: August 14, 2022 at 2:33 am
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -
Original post:
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Posted: August 14, 2022 at 2:33 am
NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022. In addition, the Company provided an overview of recent corporate developments.
Continue reading here:
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Posted: August 14, 2022 at 2:33 am
MIAMI, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was made as a material inducement to the five employees’ entry into employment with the Company.
More here:
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted: August 14, 2022 at 2:33 am
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022
See the original post here:
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
